Journal
ANNUAL REVIEW OF MEDICINE, VOL 63
Volume 63, Issue -, Pages 185-198Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-med-040210-162544
Keywords
nanomedicine; nanotherapeutics; nanocarriers; molecular targeted nanoparticles; nano-oncology
Categories
Funding
- NCI NIH HHS [CA119349, K12 CA120780] Funding Source: Medline
- NHLBI NIH HHS [BAA-HV-10-08] Funding Source: Medline
- NIBIB NIH HHS [EB003647] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [U54CA119349] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [K08EB003647] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Nanomedicine, the application of nanotechnology to medicine, enabled the development of nanoparticle therapeutic carriers. These drug carriers are passively targeted to tumors through the enhanced permeability and retention effect, so they are ideally suited for the delivery of chemotherapeutics in cancer treatment. Indeed, advances in nanomedicine have rapidly translated into clinical practice. To date, there are five clinically approved nanoparticle chemotherapeutics for cancer and many more under clinical investigation. In this review, we discuss the various nanoparticle drug delivery platforms and the important concepts involved in nanoparticle drug delivery. We also review the clinical data on the approved nanoparticle therapeutics as well as the nanotherapeutics under clinical investigation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available